{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:58:15Z","timestamp":1787029095043,"version":"build-2736575974"},"reference-count":263,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2021-1049"],"award-info":[{"award-number":["075-15-2021-1049"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Antibodies and their derivatives (scFv, Fabs, etc.) represent a unique class of biomolecules that combine selectivity with the ability to target drug delivery. Currently, one of the most promising endeavors in this field is the development of molecular diagnostic tools and antibody-based therapeutic agents, including antibody\u2013drug conjugates (ADCs). To meet this challenge, it is imperative to advance methods for modifying antibodies. A particularly promising strategy involves the introduction of carbonyl groups into the antibody that are amenable to further modification by biorthogonal reactions, namely aliphatic, aromatic, and \u03b1-oxo aldehydes, as well as aliphatic and aryl\u2013alkyl ketones. In this review, we summarize the preparation methods and applications of site-specific antibody conjugates that are synthesized using this approach.<\/jats:p>","DOI":"10.3390\/molecules28237890","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T08:36:59Z","timestamp":1701419819000},"page":"7890","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Introduction of Carbonyl Groups into Antibodies"],"prefix":"10.3390","volume":"28","author":[{"given":"Evgeny L.","family":"Gulyak","sequence":"first","affiliation":[{"name":"Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Miklukho-Maklaya 16\/10, 117997 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-5890","authenticated-orcid":false,"given":"Vera A.","family":"Alferova","sequence":"additional","affiliation":[{"name":"Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Miklukho-Maklaya 16\/10, 117997 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-6561","authenticated-orcid":false,"given":"Vladimir A.","family":"Korshun","sequence":"additional","affiliation":[{"name":"Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Miklukho-Maklaya 16\/10, 117997 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-7766","authenticated-orcid":false,"given":"Ksenia A.","family":"Sapozhnikova","sequence":"additional","affiliation":[{"name":"Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Miklukho-Maklaya 16\/10, 117997 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"ref_1","unstructured":"Meares, C.F. (2014). Reference Module in Chemistry, Molecular Sciences and Chemical Engineering, Elsevier."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2174\/138527210790069839","article-title":"Advances in Bioconjugation","volume":"14","author":"Kalia","year":"2010","journal-title":"Curr. Org. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Narain, R. (2014). Chemistry of Bioconjugates: Synthesis, Characterization, and Biomedical Applications, Wiley. [1st ed.].","DOI":"10.1002\/9781118775882"},{"key":"ref_4","unstructured":"Hermanson, G.T. (2013). Bioconjugate Techniques, Elsevier."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Algar, W.R., Dawson, P., and Medintz, I.L. (2017). Chemoselective and Bioorthogonal Ligation Reactions, Wiley-VCH.","DOI":"10.1002\/9783527683451"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nchembio0605-13","article-title":"Chemistry in Living Systems","volume":"1","author":"Prescher","year":"2005","journal-title":"Nat. Chem. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1021\/bi9007726","article-title":"Click Chemistry and Bioorthogonal Reactions: Unprecedented Selectivity in the Labeling of Biological Molecules","volume":"48","author":"Best","year":"2009","journal-title":"Biochemistry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1002\/anie.200900942","article-title":"Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality","volume":"48","author":"Sletten","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1126\/science.287.5460.2007","article-title":"Cell Surface Engineering by a Modified Staudinger Reaction","volume":"287","author":"Saxon","year":"2000","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nature02791","article-title":"Chemical Remodelling of Cell Surfaces in Living Animals","volume":"430","author":"Prescher","year":"2004","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1073\/pnas.1632821100","article-title":"A Chemical Approach for Identifying O -GlcNAc-Modified Proteins in Cells","volume":"100","author":"Vocadlo","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1021\/ja037692m","article-title":"Probing Glycosyltransferase Activities with the Staudinger Ligation","volume":"126","author":"Hang","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","article-title":"Advances in Antibody-Based Therapy in Oncology","volume":"4","author":"Zinn","year":"2023","journal-title":"Nat. Cancer."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Arlotta, K.J., and Owen, S.C. (2019). Antibody and Antibody Derivatives as Cancer Therapeutics. Wiley Interdiscipl. Rev. Nanomed. Nanobiotechnol., 11.","DOI":"10.1002\/wnan.1556"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jin, B., Odongo, S., Radwanska, M., and Magez, S. (2023). Nanobodies: A Review of Generation, Diagnostics and Therapeutics. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065994"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific Antibodies and Their Applications","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijbiomac.2020.11.058","article-title":"Bispecific Monoclonal Antibodies for Targeted Immunotherapy of Solid Tumors: Recent Advances and Clinical Trials","volume":"167","author":"Hosseini","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1389201043489602","article-title":"Antibodies in Diagnostic Applications","volume":"5","author":"Tetin","year":"2004","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1586\/14737159.2014.866039","article-title":"The Application of Monoclonal Antibodies in Cancer Diagnosis","volume":"14","author":"Zhang","year":"2014","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"938","DOI":"10.7150\/thno.37443","article-title":"Monoclonal Antibody-Based Molecular Imaging Strategies and Theranostic Opportunities","volume":"10","author":"Dammes","year":"2020","journal-title":"Theranostics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the Approval of Cancer Therapies by the FDA in the Twenty-First Century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1126\/science.2047874","article-title":"Monoclonal Antibodies in Diagnosis and Therapy","volume":"252","author":"Waldmann","year":"1991","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody Drug Conjugate: The \u201cBiological Missile\u201d for Targeted Cancer Therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Sign. Transduct. Target Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013Drug Conjugates Come of Age in Oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gogia, P., Ashraf, H., Bhasin, S., and Xu, Y. (2023). Antibody\u2013Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers, 15.","DOI":"10.3390\/cancers15153886"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ahmadi, S.E., Shabannezhad, A., Kahrizi, A., Akbar, A., Safdari, S.M., Hoseinnezhad, T., Zahedi, M., Sadeghi, S., Mojarrad, M.G., and Safa, M. (2023). Tissue Factor (Coagulation Factor III): A Potential Double-Edge Molecule to Be Targeted and Re-Targeted toward Cancer. Biomark. Res., 11.","DOI":"10.1186\/s40364-023-00504-6"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","article-title":"An Antibody\u2013Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors","volume":"74","author":"Breij","year":"2014","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.6004\/jadpro.2023.14.2.4","article-title":"Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events","volume":"14","author":"Arn","year":"2023","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab Vedotin: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an Anti-CD30\u2013Monomethyl Auristatin E Conjugate with Potent and Selective Antitumor Activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/13543784.2011.641532","article-title":"Brentuximab Vedotin (SGN-35), an Antibody\u2013Drug Conjugate for the Treatment of CD30-Positive Malignancies","volume":"21","author":"Gualberto","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab Vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-Targeted Chemotherapy with CMC-544: A CD22-Targeted Immunoconjugate of Calicheamicin for the Treatment of B-Lymphoid Malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/leu.2009.77","article-title":"CMC-544 (Inotuzumab Ozogamicin), an Anti-CD22 Immuno-Conjugate of Calicheamicin, Alters the Levels of Target Molecules of Malignant B-Cells","volume":"23","author":"Takeshita","year":"2009","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/j.clml.2020.12.008","article-title":"Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed\/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis","volume":"21","author":"Li","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2146\/ajhp130342","article-title":"Ado-Trastuzumab Emtansine for the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer","volume":"71","author":"Patel","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/1758834014539183","article-title":"Ado-Trastuzumab Emtansine (T-DM1) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer: Latest Evidence and Clinical Potential","volume":"6","author":"Peddi","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody\u2013Cytotoxic Drug Conjugate","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11912-002-0030-2","article-title":"Gemtuzumab Ozogamicin in the Treatment of Acute Myeloid Leukemia","volume":"4","author":"Stadtmauer","year":"2002","journal-title":"Curr. Oncol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12185-020-03023-4","article-title":"Clinical Outcomes of Gemtuzumab Ozogamicin for Relapsed Acute Myeloid Leukemia: Single-Institution Experience","volume":"113","author":"Hosono","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Yu, B., and Liu, D. (2019). Gemtuzumab Ozogamicin and Novel Antibody-Drug Conjugates in Clinical Trials for Acute Myeloid Leukemia. Biomark. Res., 7.","DOI":"10.1186\/s40364-019-0175-x"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12185-013-1365-1","article-title":"Efficacy and Resistance of Gemtuzumab Ozogamicin for Acute Myeloid Leukemia","volume":"97","author":"Takeshita","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-3-319-13081-1_10","article-title":"Mylotarg: Revisiting Its Clinical Potential Post-Withdrawal","volume":"Volume 17","author":"Wang","year":"2015","journal-title":"Antibody-Drug Conjugates"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00259-007-0372-y","article-title":"EANM Procedure Guideline for Radio-Immunotherapy for B-Cell Lymphoma with 90Y-Radiolabelled Ibritumomab Tiuxetan (Zevalin)","volume":"34","author":"Tennvall","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.critrevonc.2016.07.008","article-title":"Zevalin\u00ae (Ibritumomab Tiuxetan): After More than a Decade of Treatment Experience, What Have We Learned?","volume":"105","author":"Rizzieri","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.seminoncol.2005.01.012","article-title":"Use of 90Y-Ibritumomab Tiuxetan in Non-Hodgkin\u2019s Lymphoma","volume":"32","author":"Marcus","year":"2005","journal-title":"Semin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized Controlled Trial of Yttrium-90\u2013Labeled Ibritumomab Tiuxetan Radioimmunotherapy versus Rituximab Immunotherapy for Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1080\/10428190310001616944","article-title":"Radioimmunotherapy for NHL: Experience of 90Y-Ibritumomab Tiuxetan in Clinical Practice","volume":"44","author":"Hagenbeek","year":"2003","journal-title":"Leuk. Lymphoma."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Yip, V., Lee, M.V., Saad, O.M., Ma, S., Khojasteh, S.C., and Shen, B.-Q. (2021). Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY\u00ae) Antibody\u2013Drug Conjugate in Sprague Dawley Rats. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061323"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2\/SN-38 Antibody\u2013Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14737140.2019.1654378","article-title":"Sacituzumab Govitecan: Breakthrough Targeted Therapy for Triple-Negative Breast Cancer","volume":"19","author":"Weiss","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab Govitecan (IMMU-132), an anti-Trop-2-SN-38 Antibody-drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase I\/II IMMU-132-01 Basket Trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody\u2013Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Satpayev","year":"2016","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/13543784.2019.1667332","article-title":"Enfortumab Vedotin, a Fully Human Monoclonal Antibody against Nectin 4 Conjugated to Monomethyl Auristatin E for Metastatic Urothelial Carcinoma","volume":"28","author":"McGregor","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/14712598.2021.1865910","article-title":"Enfortumab Vedotin\u2013next Game-Changer in Urothelial Cancer","volume":"21","author":"Maas","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.COT.0000931988.98268.c3","article-title":"Mirvetuximab Soravtansine-Gynx (ElahereTM)","volume":"45","author":"Spreen","year":"2023","journal-title":"Oncol. Times"},{"key":"ref_59","first-page":"891","article-title":"A Review on Chemistry, Mechanism, Clinical Trials Studies of ELAHERE (Mirvetuximab Soravtansine-Gynx): A Novel FDA Approved Drug to Treat Ovarian Cancer","volume":"12","author":"Parvez","year":"2023","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","article-title":"Mirvetuximab Soravtansine: First Approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Nwabufo, C.K. (Cancer Chemother. Pharmacol., 2023). Mirvetuximab Soravtansine in Ovarian Cancer Therapy: Expert Opinion on Pharmacological Considerations, Cancer Chemother. Pharmacol., online ahead of print.","DOI":"10.1007\/s00280-023-04575-y"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10637-020-00995-2","article-title":"A Phase II Study of Mirvetuximab Soravtansine in Triple-Negative Breast Cancer","volume":"39","author":"Yam","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab Deruxtecan in Metastatic Breast Cancer with Variable HER2 Expression: The Phase 2 DAISY Trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.clbc.2020.08.006","article-title":"Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer","volume":"21","author":"Andrikopoulou","year":"2021","journal-title":"Clin. Breast Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander Killing Effect of DS -8201a, a Novel Anti-human Epidermal Growth Factor Receptor 2 Antibody\u2013Drug Conjugate, in Tumors with Human Epidermal Growth Factor Receptor 2 Heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab Mafodotin: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013Drug Conjugate, GSK2857916, in Relapsed\/Refractory Multiple Myeloma: An Update on Safety and Efficacy from Dose Expansion Phase I Study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_68","first-page":"303","article-title":"The Antibody-Drug Conjugate Loncastuximab Tesirine for the Treatment of Diffuse Large B-Cell Lymphoma","volume":"140","author":"Calabretta","year":"2022","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","article-title":"Loncastuximab Tesirine: First Approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00228-021-03253-3","article-title":"Loncastuximab Tesirine: An Effective Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"78","author":"Xu","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD Dimer\u2013Containing Antibody Drug Conjugate Targeting CD19-Expressing Malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The Discovery and Development of Brentuximab Vedotin for Use in Relapsed Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/acs.bioconjchem.3c00374","article-title":"The Evolving Landscape of Antibody\u2013Drug Conjugates: In Depth Analysis of Recent Research Progress","volume":"34","author":"Sasso","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Song, C.H., Jeong, M., In, H., Kim, J.H., Lin, C.-W., and Han, K.H. (2023). Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy. Antibodies, 12.","DOI":"10.3390\/antib12040072"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to Watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"mAbs"},{"key":"ref_76","unstructured":"Murphy, K.M., Weaver, C., Berg, L.J., and Janeway, C. (2022). Janeway\u2019s Immunobiology, W.W. Norton & Company. [10th ed.]. International Student Edition."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0304-4165(84)90408-2","article-title":"Attachment of Immunoglobulin to Liposomal Membrane via Protein Carbohydrate","volume":"800","author":"Chua","year":"1984","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0161-5890(82)90200-0","article-title":"Structural Studies of Immunoglobulins Spin-Labeled at the Carbohydrate Moiety","volume":"19","author":"Nezlin","year":"1982","journal-title":"Mol. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.immuni.2023.09.013","article-title":"Targeting Intracellular Oncoproteins with Dimeric IgA Promotes Expulsion from the Cytoplasm and Immune-Mediated Control of Epithelial Cancers","volume":"56","author":"Biswas","year":"2023","journal-title":"Immunity"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3389\/fimmu.2017.01751","article-title":"Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy","volume":"8","author":"Almagro","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG Subclasses and Allotypes: From Structure to Effector Functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1196970","DOI":"10.3389\/fimmu.2023.1196970","article-title":"Bispecific Antibody Targeting TGF-\u03b2 and PD-L1 for Synergistic Cancer Immunotherapy","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","article-title":"Bispecific Antibodies for Targeted Delivery of Anti-Cancer Therapeutic Agents: A Review","volume":"359","author":"Beishenaliev","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"626616","DOI":"10.3389\/fimmu.2021.626616","article-title":"Bispecific Antibodies: From Research to Clinical Application","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Shim, H. (2020). Bispecific Antibodies and Antibody\u2013Drug Conjugates for Cancer Therapy: Technological Considerations. Biomolecules, 10.","DOI":"10.3390\/biom10030360"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific Antibodies: A Mechanistic Review of the Pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41570-020-00241-6","article-title":"The Renaissance of Chemically Generated Bispecific Antibodies","volume":"5","author":"Szijj","year":"2021","journal-title":"Nat. Rev. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current Landscape and Future Directions of Bispecific Antibodies in Cancer Immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/acs.molpharmaceut.6b00995","article-title":"Efficient Preparation of Site-Specific Antibody\u2013Drug Conjugates Using Cysteine Insertion","volume":"14","author":"Dimasi","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1158\/1535-7163.MCT-16-0658","article-title":"Bispecific Antibodies and Antibody\u2013Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs","volume":"16","author":"Andreev","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"10585","DOI":"10.1002\/anie.201405702","article-title":"Cysteine-Selective Reactions for Antibody Conjugation","volume":"53","author":"Cal","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The Immunogenicity of Humanized and Fully Human Antibodies: Residual Immunogenicity Resides in the CDR Regions","volume":"2","author":"Harding","year":"2010","journal-title":"mAbs"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Doevendans, E., and Schellekens, H. (2019). Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies. Antibodies, 8.","DOI":"10.3390\/antib8010021"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/02648725.2013.801235","article-title":"Antibody Humanization Methods\u2014A Review and Update","volume":"29","author":"Safdari","year":"2013","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-Specific Antibody Drug Conjugates for Cancer Therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"mAbs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF02899970","article-title":"The Immunoglobulin Hinge (Interdomain) Region","volume":"6","author":"Adlersberg","year":"1976","journal-title":"Ric. Clin. Lab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4161\/mabs.4.1.18347","article-title":"Disulfide Bond Structures of IgG Molecules: Structural Variations, Chemical Modifications and Possible Impacts to Stability and Biological Function","volume":"4","author":"Liu","year":"2012","journal-title":"mAbs"},{"key":"ref_98","first-page":"1098","article-title":"La R\u00e9gion Charni\u00e8re Des Anticorps Th\u00e9rapeutiques: L\u2019importance Capitale d\u2019une Courte S\u00e9quence","volume":"35","author":"Deveuve","year":"2019","journal-title":"Med. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.bbapap.2014.07.005","article-title":"Engineering Disulfide Bonds within an Antibody","volume":"1844","author":"Hagihara","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/cbic.202000092","article-title":"Breaking a Couple: Disulfide Reducing Agents","volume":"21","author":"Mthembu","year":"2020","journal-title":"ChemBioChem"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1021\/acs.bioconjchem.1c00213","article-title":"Cysteine-Based Coupling: Challenges and Solutions","volume":"32","author":"You","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cbic.201500667","article-title":"Chemical Protein Modification through Cysteine","volume":"17","author":"Gunnoo","year":"2016","journal-title":"ChemBioChem"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1039\/C6SC00170J","article-title":"Construction of Homogeneous Antibody\u2013Drug Conjugates Using Site-Selective Protein Chemistry","volume":"7","author":"Akkapeddi","year":"2016","journal-title":"Chem. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1039\/C6OB00778C","article-title":"Site-Selective Incorporation and Ligation of Protein Aldehydes","volume":"14","author":"Spears","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"10358","DOI":"10.1021\/acs.chemrev.7b00090","article-title":"Oximes and Hydrazones in Bioconjugation: Mechanism and Catalysis","volume":"117","author":"Kool","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0022-1759(87)90120-7","article-title":"Labeling of the Oligosaccharide Moieties of Immunoglobulins","volume":"99","author":"Quarles","year":"1987","journal-title":"J. Immunol. Meth."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1177\/22.12.1084","article-title":"Peroxidase-Labeled Antibody a New Method of Conjugation","volume":"22","author":"Nakane","year":"1974","journal-title":"J. Histochem Cytochem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1126\/science.1060077","article-title":"Expanding the Genetic Code of Escherichia coli","volume":"292","author":"Wang","year":"2001","journal-title":"Science"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2021.02.001","article-title":"IgG N-Glycans","volume":"Volume 105","author":"Liu","year":"2021","journal-title":"Advances in Clinical Chemistry"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Zhong, X., D\u2019Antona, A.M., Scarcelli, J.J., and Rouse, J.C. (2022). New Opportunities in Glycan Engineering for Therapeutic Proteins. Antibodies, 11.","DOI":"10.3390\/antib11010005"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1073\/pnas.83.8.2632","article-title":"Site-Specific Covalent Modification of Monoclonal Antibodies: In Vitro and in Vivo Evaluations","volume":"83","author":"Rodwell","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/07388551.2020.1869684","article-title":"Characterization of Glycosylation in Monoclonal Antibodies and Its Importance in Therapeutic Antibody Development","volume":"41","author":"Kaur","year":"2021","journal-title":"Crit. Rev. Biotechnol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1074\/mcp.R112.026005","article-title":"Glycoproteomic Analysis of Antibodies","volume":"12","author":"Zauner","year":"2013","journal-title":"Mol. Cell Proteomics."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-biochem-062917-012911","article-title":"Glycoengineering of Antibodies for Modulating Functions","volume":"88","author":"Wang","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13238-017-0433-3","article-title":"Glycosylation Engineering of Therapeutic IgG Antibodies: Challenges for the Safety, Functionality and Efficacy","volume":"9","author":"Mimura","year":"2018","journal-title":"Protein Cell"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Boune, S., Hu, P., Epstein, A.L., and Khawli, L.A. (2020). Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations. Antibodies, 9.","DOI":"10.3390\/antib9020022"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/glycob\/cwz085","article-title":"On Enzymatic Remodeling of IgG Glycosylation; Unique Tools with Broad Applications","volume":"30","author":"Lood","year":"2020","journal-title":"Glycobiology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"929895","DOI":"10.3389\/fimmu.2022.929895","article-title":"Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies","volume":"13","author":"Golay","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/19420862.2015.1117719","article-title":"Glycan Analysis of Therapeutic Glycoproteins","volume":"8","author":"Zhang","year":"2016","journal-title":"mAbs"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/pmic.200800715","article-title":"IgG Glycosylation Analysis","volume":"9","author":"Huhn","year":"2009","journal-title":"Proteomics"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.12.002","article-title":"Glycans in the Immune System and The Altered Glycan Theory of Autoimmunity: A Critical Review","volume":"57","author":"Maverakis","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00018-016-2366-z","article-title":"Regulation of Antibody Effector Functions through IgG Fc N-Glycosylation","volume":"74","author":"Quast","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4049\/jimmunol.1502136","article-title":"The Emerging Importance of IgG Fab Glycosylation in Immunity","volume":"196","author":"Hafkenscheid","year":"2016","journal-title":"J. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"818736","DOI":"10.3389\/fimmu.2022.818736","article-title":"Sialylation as an Important Regulator of Antibody Function","volume":"13","author":"Vattepu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0165-2478(84)90008-7","article-title":"A Novel Procedure for Labeling Immunoglobulins by Conjugation to Oligosaccharide Moieties","volume":"8","author":"Dobersen","year":"1984","journal-title":"Immunol. Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-4939-6972-2_14","article-title":"Engineer Medium and Feed for Modulating N-Glycosylation of Recombinant Protein Production in CHO Cell Culture","volume":"Volume 1603","author":"Meleady","year":"2017","journal-title":"Heterologous Protein Production in CHO Cells"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/abio.1997.2036","article-title":"Characterization of Monoclonal Antibody Glycosylation: Comparison of Expression Systems and Identification of Terminal \u03b1-Linked Galactose","volume":"247","author":"Sheeley","year":"1997","journal-title":"Anal. Biochem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/bit.24959","article-title":"CHO Cell Line Specific Prediction and Control of Recombinant Monoclonal Antibody N-glycosylation","volume":"110","author":"Grainger","year":"2013","journal-title":"Biotechnol. Bioeng."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/A:1018589704981","article-title":"The Glycosylation Pattern of a Humanized IgGl Antibody (D1.3) Expressed in CHO Cells","volume":"14","author":"Routier","year":"1997","journal-title":"Glycoconj. J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00253-009-2152-z","article-title":"Glycosylation Pattern of Humanized IgG-like Bispecific Antibody Produced by Recombinant CHO Cells","volume":"85","author":"Kim","year":"2010","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0021-9258(18)81196-6","article-title":"Glycopeptides. IV. The Periodate Oxidation of Glycopeptides from Human Gamma-Globulin","volume":"238","author":"Rothfus","year":"1963","journal-title":"J. Biol. Chem."},{"key":"ref_133","unstructured":"(2010). Comprehensive Organic Name Reactions and Reagents, Wiley."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1021\/ja01875a521","article-title":"The Action of Periodic Acid on \u03b1-Amino Alcohols","volume":"61","author":"Nicolet","year":"1939","journal-title":"J. Am. Chem. Soc."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1039\/c2cc32412a","article-title":"Fucose-Specific Conjugation of Hydrazide Derivatives to a Vascular-Targeting Monoclonal Antibody in IgG Format","volume":"48","author":"Casi","year":"2012","journal-title":"Chem. Commun."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/abio.1995.1511","article-title":"Studies on the Rate and Control of Antibody Oxidation by Periodate","volume":"231","author":"Wolfe","year":"1995","journal-title":"Anal. Biochem."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Sapozhnikova, K.A., Gulyak, E.L., Misyurin, V.A., Simonova, M.A., Ryabukhina, E.V., Alexeeva, A.V., Tikhonova, N.A., Lyzhko, N.A., Popova, G.P., and Misyurin, A.V. (2023). Branched Linkers for Site-Specific Fluorescent Labeling of Antibodies. Molecules, 28.","DOI":"10.3390\/molecules28010425"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"9638","DOI":"10.1016\/j.tet.2012.09.062","article-title":"A New Bioorthogonal Cross-Linker with Alkyne and Hydrazide End Groups for Chemoselective Ligation. Application to Antibody Labelling","volume":"68","author":"Salmain","year":"2012","journal-title":"Tetrahedron"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-1759(91)90233-6","article-title":"The Influence of Periodate Oxidation on Monoclonal Antibody Avidity and Immunoreactivity","volume":"144","author":"Abraham","year":"1991","journal-title":"J. Immunol. Meth."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0161-5890(78)90003-2","article-title":"Modification of Immunoglobulin G Using Specific Reactivity of Sugar Moiety","volume":"15","author":"Akira","year":"1978","journal-title":"Immunochemistry"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1021\/jm00061a017","article-title":"Site-Specific Conjugation of a Radioiodinated Phenethylamine Derivative to a Monoclonal Antibody Results in Increased Radioactivity Localization in Tumor","volume":"36","author":"Kurth","year":"1993","journal-title":"J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"913","DOI":"10.4049\/jimmunol.97.6.913","article-title":"Effects of Mild Periodate Oxidation on Antibodies","volume":"97","author":"Andersen","year":"1966","journal-title":"J. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/bc400505q","article-title":"Site-Specific Antibody\u2013Drug Conjugation through Glycoengineering","volume":"25","author":"Zhou","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-5793(79)81095-9","article-title":"The Identification of Tryptophan Residues in Proteins as Oxidised Derivatives during Amino Acid Sequence Determinations","volume":"104","author":"Inglis","year":"1979","journal-title":"FEBS Lett."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1042\/bj0940017","article-title":"The Periodate Oxidation of Amino Acids with Reference to Studies on Glycoproteins","volume":"94","author":"Clamp","year":"1965","journal-title":"Biochem. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1039\/a701844d","article-title":"Simultaneous Determination of Products and Intermediates of L-Dopa Oxidation Using Capillary Electrophoresis With Diode-Array Detection","volume":"122","author":"Robinson","year":"1997","journal-title":"Analyst"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1042\/bj2470467","article-title":"The Cross-Linking of Tyrosine Residues in Apo-Ovotransferrin by Treatment with Periodate Anions","volume":"247","author":"Hsuan","year":"1987","journal-title":"Biochem. J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0076-6879(95)58057-3","article-title":"Role of Oxidized Amino Acids in Protein Breakdown and Stability","volume":"Volume 258","author":"Stadtman","year":"1995","journal-title":"Methods in Enzymology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1110\/ps.44201","article-title":"Reactivity of Peptidyl-tyrosine to Hydroxylation and Cross-linking","volume":"10","author":"Burzio","year":"2001","journal-title":"Protein Sci."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0003-2697(82)90127-0","article-title":"Periodate Oxidation of Methionine in Proteins","volume":"126","author":"Yamasaki","year":"1982","journal-title":"Anal. Biochem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-5793(77)80423-7","article-title":"Specific Spin Labelling of the Fc Region of Immunoglobulins","volume":"80","author":"Willan","year":"1977","journal-title":"FEBS Lett."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1021\/acs.bioconjchem.5b00173","article-title":"Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases","volume":"26","author":"Qasba","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11095-018-2545-8","article-title":"Impact of Tryptophan Oxidation in Complementarity-Determining Regions of Two Monoclonal Antibodies on Structure-Function Characterized by Hydrogen-Deuterium Exchange Mass Spectrometry and Surface Plasmon Resonance","volume":"36","author":"Hageman","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1021\/jm901128z","article-title":"Synthesis and Structure\u2212Activity Relationships of Dimeric Peptide Antagonists of the Human Immunoglobulin G\u2212Human Neonatal Fc Receptor (IgG\u2212FcRn) Interaction","volume":"53","author":"McDonnell","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/6179","article-title":"Engineered Glycoforms of an Antineuroblastoma IgG1 with Optimized Antibody-Dependent Cellular Cytotoxic Activity","volume":"17","author":"Moudry","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02921504","article-title":"Single Step Oxidative Binding of Antibodies to Hydrazide-Modified Eupergit C","volume":"26","author":"Fleminger","year":"1990","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0021-9673(01)93734-3","article-title":"Hydrazido-Derivatized Supports in Affinity Chromatography","volume":"510","year":"1990","journal-title":"J. Chromatogr. A"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF02798382","article-title":"Oriented Immobilization of Periodateoxidized Monoclonal Antibodies on Amino and Hydrazide Derivatives of Eupergit C","volume":"23","author":"Fleminger","year":"1990","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0022-1759(88)90041-5","article-title":"Site-Specific Immobilization of Antibodies by Their Oligosaccharide Moieties to New Hydrazide Derivatized Solid Supports","volume":"112","author":"Hoffman","year":"1988","journal-title":"J. Immunol. Meth."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1021\/cb6003959","article-title":"Regioselective Labeling of Antibodies through N-Terminal Transamination","volume":"2","author":"Scheck","year":"2007","journal-title":"ACS Chem. Biol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1039\/C2SC21365F","article-title":"Synthetically Modified Fc Domains as Building Blocks for Immunotherapy Applications","volume":"4","author":"Netirojjanakul","year":"2013","journal-title":"Chem. Sci."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/9780470559277.ch100018","article-title":"Site-Specific Protein Bioconjugation via a Pyridoxal 5\u2032-Phosphate-Mediated N-Terminal Transamination Reaction","volume":"2","author":"Witus","year":"2010","journal-title":"Curr. Prot. Chem. Biol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"17223","DOI":"10.1021\/ja408868a","article-title":"Site-Specific Protein Transamination Using N -Methylpyridinium-4-Carboxaldehyde","volume":"135","author":"Witus","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/19420862.2019.1655377","article-title":"Impact of Fc N-Glycan Sialylation on IgG Structure","volume":"11","author":"Zhang","year":"2019","journal-title":"mAbs"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0065-2318(08)60109-2","article-title":"Chemistry, Metabolism, and Biological Functions of Sialic Acids","volume":"Volume 40","author":"Schauer","year":"1982","journal-title":"Advances in Carbohydrate Chemistry and Biochemistry"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1042\/bj2780311","article-title":"Some Questions and Suggestions on the Type References of the Official Nomenclature (IUB) for Sialidase(s) and Endosialidase","volume":"278","author":"Cabezas","year":"1991","journal-title":"Biochem. J."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"40860","DOI":"10.18632\/oncotarget.8396","article-title":"Neuraminidase-1: A Novel Therapeutic Target in Multistage Tumorigenesis","volume":"7","author":"Haxho","year":"2016","journal-title":"Oncotarget"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human Fc\u03b3RIII and Antibody-Dependent Cellular Toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.4161\/mabs.29889","article-title":"Site-Specific Antibody-Drug Conjugation through an Engineered Glycotransferase and a Chemically Reactive Sugar","volume":"6","author":"Zhu","year":"2014","journal-title":"mAbs"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/nprot.2017.058","article-title":"Chemoenzymatic Synthesis of Glycoengineered IgG Antibodies and Glycosite-Specific Antibody\u2013Drug Conjugates","volume":"12","author":"Tang","year":"2017","journal-title":"Nat. Protoc."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1073\/pnas.1702173114","article-title":"Modulating IgG Effector Function by Fc Glycan Engineering","volume":"114","author":"Li","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"16508","DOI":"10.1074\/jbc.M116.738765","article-title":"Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling","volume":"291","author":"Li","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3762\/bjoc.14.30","article-title":"Synthetic and Semi-Synthetic Approaches to Unprotected N -Glycan Oxazolines","volume":"14","author":"Fairbanks","year":"2018","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.bmc.2017.07.053","article-title":"One-Pot Enzymatic Glycan Remodeling of a Therapeutic Monoclonal Antibody by Endoglycosidase S (Endo-S) from Streptococcus Pyogenes","volume":"26","author":"Tong","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"12023","DOI":"10.1073\/pnas.1812833115","article-title":"Site-Selective Chemoenzymatic Glycoengineering of Fab and Fc Glycans of a Therapeutic Antibody","volume":"115","author":"Giddens","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1039\/C9QO00646J","article-title":"New Linker Structures Applied in Glycosite-Specific Antibody Drug Conjugates","volume":"6","author":"Faridoon","year":"2019","journal-title":"Org. Chem. Front."},{"key":"ref_177","first-page":"97","article-title":"Purification and Characterization of a Novel Fungal Endo-\u03b2-N-Acetylglucosaminidase Acting on Complex Oligosaccharides of Glycoproteins","volume":"54","author":"Kadowaki","year":"1990","journal-title":"Agric. Biol. Chem."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1006\/bbrc.1994.2174","article-title":"Transglycosylation Activity of Mucor Hiemalis Endo-\u03b2-N-Acetylglucosaminidase Which Transfers Complex Oligosaccharides to the N-acetylglucosamine Moieties of Peptides","volume":"203","author":"Yamamoto","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0008-6215(96)91025-3","article-title":"Transglycosylation of Intact Sialo Complex-Type Oligosaccharides to the N-acetylglucosamine Moieties of Glycopeptides by Mucor Hiemalis Endo-\u03b2-N-Acetylglucosaminidase","volume":"292","author":"Haneda","year":"1996","journal-title":"Carbohydr. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0040-4039(97)10487-7","article-title":"A Synthesis of a Glycopeptide Analogue of Eel Calcitonin","volume":"39","author":"Mizuno","year":"1998","journal-title":"Tetrahedron Lett."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1389-1723(01)80307-8","article-title":"Chemo-Enzymatic Synthesis of Bioactive Glycopeptide Using Microbial Endoglycosidase","volume":"92","author":"Yamamoto","year":"2001","journal-title":"J. Biosci. Bioeng."},{"key":"ref_182","first-page":"84","article-title":"Attempts to Synthesize Homogeneous Glycan-Conjugated Antibody-Drug Conjugates","volume":"2","author":"Manabe","year":"2020","journal-title":"Transl. Regul. Sci."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.bbagen.2016.04.016","article-title":"Immune Recruitment or Suppression by Glycan Engineering of Endogenous and Therapeutic Antibodies","volume":"1860","author":"Le","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.chembiol.2015.12.007","article-title":"Glycan Engineering for Cell and Developmental Biology","volume":"23","author":"Griffin","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/cb200429n","article-title":"Emerging Technologies for Making Glycan-Defined Glycoproteins","volume":"7","author":"Wang","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.copbio.2019.01.012","article-title":"Why Recombinant Antibodies\u2014Benefits and Applications","volume":"60","author":"Basu","year":"2019","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-1759(80)90146-5","article-title":"Production of Monoclonal Antibodies: Strategy and Tactics","volume":"35","author":"Scheidegger","year":"1980","journal-title":"J. Immunol. Meth."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"110376","DOI":"10.1016\/j.intimp.2023.110376","article-title":"Production of Monoclonal Antibodies for Therapeutic Purposes: A Review","volume":"120","author":"Alejandra","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"112807","DOI":"10.1016\/j.jim.2020.112807","article-title":"Facile Generation of Monoclonal Antibodies Suitable for Conjugation","volume":"483","author":"Bjerrum","year":"2020","journal-title":"J. Immunol. Meth."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ijbiomac.2019.06.006","article-title":"Phage Display Antibody Libraries: A Robust Approach for Generation of Recombinant Human Monoclonal Antibodies","volume":"135","author":"Kumar","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_191","unstructured":"Hentrich, C., Ylera, F., Frisch, C., Ten Haaf, A., and Knappik, A. (2018). Handbook of Immunoassay Technologies, Elsevier."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Reichl, F.-X., and Schwenk, M. (2021). Regulatory Toxicology, Springer International Publishing.","DOI":"10.1007\/978-3-030-57499-4"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","article-title":"Engineering Therapeutic Bispecific Antibodies Using CrossMab Technology","volume":"154","author":"Klein","year":"2019","journal-title":"Methods"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","article-title":"Challenges and Strategies for Next-Generation Bispecific Antibody-Based Antitumor Therapeutics","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Wang, Q., Chen, Y., Park, J., Liu, X., Hu, Y., Wang, T., McFarland, K., and Betenbaugh, M.J. (2019). Design and Production of Bispecific Antibodies. Antibodies, 8.","DOI":"10.3390\/antib8030043"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/febs.15515","article-title":"A Guide to: Generation and Design of Nanobodies","volume":"288","author":"Muyldermans","year":"2021","journal-title":"FEBS J."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"105645","DOI":"10.1016\/j.pep.2020.105645","article-title":"Recombinant Expression of Nanobodies and Nanobody-Derived Immunoreagents","volume":"172","year":"2020","journal-title":"Protein Expr. Purif."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-1759(00)00342-2","article-title":"Design and Application of Diabodies, Triabodies and Tetrabodies for Cancer Targeting","volume":"248","author":"Todorovska","year":"2001","journal-title":"J. Immunol. Meth."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-62703-586-6_10","article-title":"Production of Stabilized scFv Antibody Fragments in the E. coli Bacterial Cytoplasm","volume":"Volume 1060","author":"Steinitz","year":"2014","journal-title":"Human Monoclonal Antibodies"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells","volume":"Volume 1441","author":"Somanchi","year":"2016","journal-title":"Natural Killer Cells"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/protein\/3.8.703","article-title":"Site-Specific Attachment to Recombinant Antibodies via Introduced Surface Cysteine Residues","volume":"3","author":"Lyons","year":"1990","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1208\/s12248-017-0083-7","article-title":"Site Selection: A Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates","volume":"19","author":"Tumey","year":"2017","journal-title":"AAPS J."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"12047","DOI":"10.1021\/bi901744t","article-title":"Molecularly Defined Antibody Conjugation through a Selenocysteine Interface","volume":"48","author":"Hofer","year":"2009","journal-title":"Biochemistry"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1021\/acs.bioconjchem.5b00355","article-title":"Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody","volume":"26","author":"Thompson","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chembiol.2017.02.012","article-title":"Stable and Potent Selenomab-Drug Conjugates","volume":"24","author":"Li","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab Vedotin: First Global Approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature16057","article-title":"Novel Antibody\u2013Antibiotic Conjugate Eliminates Intracellular S. aureus","volume":"527","author":"Lehar","year":"2015","journal-title":"Nature"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1080\/19420862.2016.1229722","article-title":"Pharmacokinetics and Pharmacodynamics of DSTA4637A: A Novel THIOMABTM Antibody Antibiotic Conjugate against Staphylococcus aureus in Mice","volume":"8","author":"Zhou","year":"2016","journal-title":"mAbs"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1080\/19420862.2019.1627152","article-title":"Preclinical and Translational Pharmacokinetics of a Novel THIOMABTM Antibody-Antibiotic Conjugate against Staphylococcus aureus","volume":"11","author":"Deng","year":"2019","journal-title":"mAbs"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1093\/ofid\/ofaa439.477","article-title":"167. A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients with Staphylococcus Aureus Bacteremia Receiving Standard-of-Care Antibiotics","volume":"7","author":"Lim","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1016\/j.bmcl.2018.10.043","article-title":"Synthesis of a Heterotrifunctional Linker for the Site-Specific Preparation of Antibody-Drug Conjugates with Two Distinct Warheads","volume":"28","author":"Kumar","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_212","unstructured":"Department of Medicinal Chemistry, University of Utah, Nervig, C.S., Owen, S.C., Department of Molecular Pharmaceutics, University of Utah, and Department of Biomedical Engineering, University of Utah (2023). Advances in the Development of Dual-Drug Antibody Drug Conjugates. J. Antib. Drug Conjug."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1039\/C9CY01856E","article-title":"Efficient Continuous-Flow Aldehyde Tag Conversion Using Immobilized Formylglycine Generating Enzyme","volume":"10","author":"Peng","year":"2020","journal-title":"Catal. Sci. Technol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bc500189z","article-title":"Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct In Vivo Efficacy and PK Outcomes","volume":"25","author":"Drake","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1002\/anie.201814200","article-title":"Efficient Pictet\u2013Spengler Bioconjugation with N-Substituted Pyrrolyl Alanine Derivatives","volume":"58","author":"Pomplun","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1021\/acschembio.5b00315","article-title":"Self-Assembled Hybrid Aptamer-Fc Conjugates for Targeted Delivery: A Modular Chemoenzymatic Approach","volume":"10","author":"Dickgiesser","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/bc500061s","article-title":"Chemoenzymatic Fc Glycosylation via Engineered Aldehyde Tags","volume":"25","author":"Smith","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1021\/j100784a506","article-title":"The Kinetics of the Periodate Oxidation of 2-Aminoethanol","volume":"68","author":"Dahlgren","year":"1964","journal-title":"J. Phys. Chem."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.tcm.2012.07.004","article-title":"Enzymatic Antibody Tagging: Toward a Universal Biocompatible Targeting Tool","volume":"22","author":"Ta","year":"2012","journal-title":"Tr. Cardiovasc. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"25798","DOI":"10.1021\/acsomega.0c03102","article-title":"cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibody\u2013Drug Conjugate Targeting c-Met Overexpression Tumors","volume":"5","author":"Min","year":"2020","journal-title":"ACS Omega"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"2102414","DOI":"10.1002\/advs.202102414","article-title":"An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers","volume":"8","author":"Shin","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wang, Y., Uslu, S., Venkatachalapathy, S., Rashidian, M., Schaefer, J.V., Pl\u00fcckthun, A., and Distefano, M.D. (2022). Enzymatic Construction of DARPin-Based Targeted Delivery Systems Using Protein Farnesyltransferase and a Capture and Release Strategy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911537"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1021\/acs.bioconjchem.0c00151","article-title":"Introduction of an Aldehyde Handle on Nanobodies by Affinity-Guided Labeling","volume":"31","author":"Mortensen","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fchem.2014.00015","article-title":"Unnatural Amino Acid Incorporation in E. coli: Current and Future Applications in the Design of Therapeutic Proteins","volume":"2","author":"Wals","year":"2014","journal-title":"Front. Chem."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.4155\/fmc.14.79","article-title":"Unnatural Amino Acids in Novel Antibody Conjugates","volume":"6","author":"Hallam","year":"2014","journal-title":"Future Med. Chem."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1021\/acschembio.7b00974","article-title":"Playing with the Molecules of Life","volume":"13","author":"Young","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/bs.mie.2015.06.008","article-title":"Genetic Incorporation of the Unnatural Amino Acid P-Acetyl Phenylalanine into Proteins for Site-Directed Spin Labeling","volume":"Volume 563","author":"Evans","year":"2015","journal-title":"Methods in Enzymology"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/acschembio.1c00120","article-title":"Genetic Encoding of Three Distinct Noncanonical Amino Acids Using Reprogrammed Initiator and Nonsense Codons","volume":"16","author":"Tharp","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/cbic.201500673","article-title":"Cyclic Peptides Made by Linking Synthetic and Genetically Encoded Fragments","volume":"17","author":"Palei","year":"2016","journal-title":"ChemBioChem"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1073\/pnas.1321237111","article-title":"A General Approach to Site-Specific Antibody Drug Conjugates","volume":"111","author":"Tian","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1021\/acs.nanolett.8b03837","article-title":"Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-Orthogonally Conjugated Drug","volume":"19","author":"Costa","year":"2019","journal-title":"Nano Lett."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1021\/acs.bioconjchem.1c00134","article-title":"A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid","volume":"32","author":"Zhang","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"8150","DOI":"10.1021\/ja961216x","article-title":"Site-Specific Protein Modification Using a Ketone Handle","volume":"118","author":"Cornish","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1073\/pnas.0234824100","article-title":"Addition of the Keto Functional Group to the Genetic Code of Escherichia coli","volume":"100","author":"Wang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1021\/bi0300231","article-title":"A New Strategy for the Site-Specific Modification of Proteins in Vivo","volume":"42","author":"Zhang","year":"2003","journal-title":"Biochemistry"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1016\/j.bmcl.2006.07.094","article-title":"Genetic Introduction of a Diketone-Containing Amino Acid into Proteins","volume":"16","author":"Zeng","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bmcl.2009.12.077","article-title":"Genetic Incorporation of an Aliphatic Keto-Containing Amino Acid into Proteins for Their Site-Specific Modifications","volume":"20","author":"Huang","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1073\/pnas.1120682109","article-title":"Site-Specific DNA-Antibody Conjugates for Specific and Sensitive Immuno-PCR","volume":"109","author":"Kazane","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/ja309505c","article-title":"Self-Assembled Antibody Multimers through Peptide Nucleic Acid Conjugation","volume":"135","author":"Kazane","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/acs.bioconjchem.5b00111","article-title":"Antibody Microarrays Utilizing Site-Specific Antibody\u2013Oligonucleotide Conjugates","volume":"26","author":"Wold","year":"2015","journal-title":"Bioconjugate Chem."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"16101","DOI":"10.1073\/pnas.1211023109","article-title":"Synthesis of Site-Specific Antibody-Drug Conjugates Using Unnatural Amino Acids","volume":"109","author":"Axup","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"17796","DOI":"10.1073\/pnas.1316026110","article-title":"Bispecific Small Molecule\u2013Antibody Conjugate Targeting Prostate Cancer","volume":"110","author":"Kim","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"11863","DOI":"10.1002\/anie.201408103","article-title":"A CXCR4-Targeted Site-Specific Antibody\u2013Drug Conjugate","volume":"53","author":"Kularatne","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"9918","DOI":"10.1021\/ja303904e","article-title":"Synthesis of Bispecific Antibodies Using Genetically Encoded Unnatural Amino Acids","volume":"134","author":"Kim","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jmb.2011.01.011","article-title":"Site-Specific Coupling and Sterically Controlled Formation of Multimeric Antibody Fab Fragments with Unnatural Amino Acids","volume":"406","author":"Hutchins","year":"2011","journal-title":"J. Mol. Biol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1073\/pnas.1213186110","article-title":"A Pictet-Spengler Ligation for Protein Chemical Modification","volume":"110","author":"Agarwal","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/acsmedchemlett.6b00253","article-title":"Site-Specific Tandem Knoevenagel Condensation\u2013Michael Addition To Generate Antibody\u2013Drug Conjugates","volume":"7","author":"Kudirka","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.chembiol.2014.11.019","article-title":"Generating Site-Specifically Modified Proteins via a Versatile and Stable Nucleophilic Carbon Ligation","volume":"22","author":"Kudirka","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/1097-0282(2000)55:2<165::AID-BIP50>3.0.CO;2-#","article-title":"Functionalization of Peptides and Proteins by Aldehyde or Keto Groups","volume":"55","author":"Melnyk","year":"2000","journal-title":"Pept. Sci."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1021\/bc300516f","article-title":"\u03b1-Oxo Aldehyde or Glyoxylyl Group Chemistry in Peptide Bioconjugation","volume":"24","author":"Melnyk","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/psc.2874","article-title":"Oxime Conjugation in Protein Chemistry: From Carbonyl Incorporation to Nucleophilic Catalysis","volume":"22","author":"Agten","year":"2016","journal-title":"J. Pept. Sci."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1002\/anie.200802651","article-title":"Hydrolytic Stability of Hydrazones and Oximes","volume":"47","author":"Kalia","year":"2008","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/anie.201607085","article-title":"Three-Dimensional Ordered Antibody Arrays Through Self-Assembly of Antibody\u2013Polymer Conjugates","volume":"56","author":"Dong","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1021\/acschembio.8b00107","article-title":"A Switchable Site-Specific Antibody Conjugate","volume":"13","author":"Lyu","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Sapozhnikova, K.A., Misyurin, V.A., Ryazantsev, D.Y., Kokin, E.A., Finashutina, Y.P., Alexeeva, A.V., Ivanov, I.A., Kocharovskaya, M.V., Tikhonova, N.A., and Popova, G.P. (2021). Sensitive Immunofluorescent Detection of the PRAME Antigen Using a Practical Antibody Conjugation Approach. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312845"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1021\/acs.molpharmaceut.8b00225","article-title":"Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of Its Identified Metabolite","volume":"15","author":"Snyder","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"Sapozhnikova, K.A., Gulyak, E.L., Brylev, V.A., Misyurin, V.A., Oreshkov, S.D., Alexeeva, A.V., Ryazantsev, D.Y., Simonova, M.A., Ryabukhina, E.V., and Popova, G.P. (2023). Aminooxy Click Modification of a Periodate-Oxidized Immunoglobulin G: A General Approach to Antibody\u2013Drug Conjugates with Dye-Mediated Expeditious Stoichiometry Control. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065134"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1002\/anie.201306866","article-title":"Recruiting Cytotoxic T Cells to Folate-Receptor-Positive Cancer Cells","volume":"52","author":"Kularatne","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1021\/acs.bioconjchem.5b00203","article-title":"Targeted Delivery of LXR Agonist Using a Site-Specific Antibody\u2013Drug Conjugate","volume":"26","author":"Lim","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1021\/acs.bioconjchem.9b00306","article-title":"Antibody\u2013Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents","volume":"30","author":"Dovgan","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-22-0456","article-title":"Phase I Trial of a Novel Anti-HER2 Antibody\u2013Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/1538-7445.AM2023-3997","article-title":"Abstract 3997: Preclinical Characterization of ARX517, a next-Generation Anti-PSMA Antibody Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer","volume":"83","author":"Skidmore","year":"2023","journal-title":"Cancer Res."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1535-7163.MCT-21-0715","article-title":"Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-Based Antibody\u2013Drug Conjugate Targeting AXL-Expressing Cancers","volume":"21","author":"Zammarchi","year":"2022","journal-title":"Mol. Cancer Ther."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/23\/7890\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:36:03Z","timestamp":1760132163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/23\/7890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":263,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["molecules28237890"],"URL":"https:\/\/doi.org\/10.3390\/molecules28237890","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}